NO20073710L - Kjemiske forbindelser - Google Patents

Kjemiske forbindelser

Info

Publication number
NO20073710L
NO20073710L NO20073710A NO20073710A NO20073710L NO 20073710 L NO20073710 L NO 20073710L NO 20073710 A NO20073710 A NO 20073710A NO 20073710 A NO20073710 A NO 20073710A NO 20073710 L NO20073710 L NO 20073710L
Authority
NO
Norway
Prior art keywords
glycogen phosphorylase
chemical connections
activity
diabetes
consequently
Prior art date
Application number
NO20073710A
Other languages
English (en)
Inventor
Paul Robert Owen Whittamore
Craig Johnstone
Alan Martin Birch
Iain Simpson
Alleyn Plowright
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0502466A external-priority patent/GB0502466D0/en
Priority claimed from GB0502465A external-priority patent/GB0502465D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20073710L publication Critical patent/NO20073710L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

(1) En forbindelse med formel (1) eller et farmasøytisk akseptabelt salt: har glykogen-fosforylase-hemmende aktivitet og har følgelig verdi ved behandling av sykdomstilstander forbundet med øket glykogen-fosforylase-aktivitet, så som type 2 diabetes. Fremgangsmåter for fremstilling av forbindelser og farmasøytiske preparater inneholdende dem er beskrevet. ?? ?? ?? ?? 89
NO20073710A 2005-02-05 2007-07-18 Kjemiske forbindelser NO20073710L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0502466A GB0502466D0 (en) 2005-02-05 2005-02-05 Chemical compounds
GB0502465A GB0502465D0 (en) 2005-02-05 2005-02-05 Chemical compounds
PCT/GB2006/000349 WO2006082401A1 (en) 2005-02-05 2006-02-02 Chemical compounds

Publications (1)

Publication Number Publication Date
NO20073710L true NO20073710L (no) 2007-08-31

Family

ID=36178184

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073710A NO20073710L (no) 2005-02-05 2007-07-18 Kjemiske forbindelser

Country Status (11)

Country Link
US (1) US20100137397A1 (no)
EP (1) EP1848721A1 (no)
JP (1) JP2008528667A (no)
KR (1) KR20070107108A (no)
AU (1) AU2006210719A1 (no)
BR (1) BRPI0606838A2 (no)
CA (1) CA2595835A1 (no)
IL (1) IL184628A0 (no)
MX (1) MX2007009438A (no)
NO (1) NO20073710L (no)
WO (1) WO2006082401A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US8633252B2 (en) 2009-01-26 2014-01-21 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
CA2804771C (en) 2010-07-09 2018-02-20 Highlife Sas Transcatheter atrio-ventricular valve prosthesis
US20240190809A1 (en) * 2021-05-11 2024-06-13 Awakn Ls Europe Holdings Limited Therapeutic aminoindane compounds and compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
GB0318463D0 (en) * 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
KR20070107108A (ko) 2007-11-06
WO2006082401A1 (en) 2006-08-10
CA2595835A1 (en) 2006-08-10
EP1848721A1 (en) 2007-10-31
MX2007009438A (es) 2007-08-16
JP2008528667A (ja) 2008-07-31
IL184628A0 (en) 2007-12-03
US20100137397A1 (en) 2010-06-03
BRPI0606838A2 (pt) 2010-02-09
AU2006210719A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
NO20074872L (no) Pyrazoler
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
NO20082709L (no) Kjemiske forbindelser
NO20081052L (no) GSK-3 inhibitorer
NO20073719L (no) Kjemiske forbindelser
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
NO20074703L (no) Antibakterielle piperidinderivater
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
WO2007128480A3 (en) Thioglycosides as pharmaceutically active agents
NO20081196L (no) Terapeutisk middel for diabetes
NO20081211L (no) Xantinderivater som selektive HM74A agonister
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20091599L (no) Kjemiske forbindelser
NO20091683L (no) Kjemiske forbindelser
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
NO20070566L (no) Azin-karboksamider som antikreftmiddel
NO341617B1 (no) Dihydropyrazolpyrimidinonderivater, deres anvendelse i terapi og til behandling av kreft, deres anvendelse for fremstilling av et medikament, og for anvendelse som strålingssensibilisator, farmasøytisk sammensetning derav, samt et kombinert preparat for administrering ved behandling av kreft.
NO20064456L (no) Thiadiazolidinoner som GSK-3 inhibitorer
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
WO2006099943A8 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
NO20083845L (no) 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer
NO20065926L (no) Substituerte oksazolbenzoisotiazoldioksidderivater samt fremgangsmate for fremstilling og anvendelse derav
NO20082445L (no) Neuropeptid-2 reseptor-agonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application